Compare Incyte Corporation (INCY) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Open Text Corporation — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Open Text Corporation trades at $22.78 (market cap $5.61B). The key difference: Incyte Corporation is far larger — about 4.1× Open Text Corporation's market cap, and Open Text Corporation pays a 4.72% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OTEX | |
|---|---|---|
Market Cap | $23.11B | $5.61B |
Sector | Health | Technology |
52-Week High | $118.52 | $39.69 |
52-Week Low | $67.38 | $20.01 |
Enterprise Value | $19.13B | $10.77B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
OpenText (OTEX) trades at $23.33, up 0.26% with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 11.3, EV/EBITDA of 6.71, and consistent earnings beats in recent quarters. Recent developments include a $105 million European AI investment and board appointments, while maintaining a 4.7% dividend yield.
OTEX presents value opportunity with attractive valuation multiples and strong cash flow generation. Key risks include execution challenges in AI strategy and competitive software market pressures. Analyst consensus targets $29.75 (27.5% upside) with 42% buy ratings, though majority maintain hold stance awaiting clearer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
